Actively Recruiting
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
Led by East and North Hertfordshire NHS Trust · Updated on 2023-11-13
180
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prior studies have shown that impaired endogenous fibrinolysis is a novel, independent cardiovascular risk factor in patients with myocardial infarction and there is currently no known chronic treatment to enhance endogenous fibrinolysis. To date, no therapies have been able to sufficiently reduce Lp(a) and therefore it was considered to be a non-modifiable cardiovascular risk factor. New data, however, has shown that PCSK9 inhibitors and inclisiran (medication that you have been deemed eligible for in order to help further reduce your cholesterol levels) to reduce Lp(a) levels by approximately 20-25%. The aim of this study to is to assess: 1. if there is an association between raised Lp(a) level in blood and the effectiveness of endogenous fibrinolysis (lysis time). 2. whether lowering Lp(a) with PCSK9i or inclisiran can enhance endogenous fibrinolysis
CONDITIONS
Official Title
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female patients aged 18 years or over
- Patients eligible for treatment with PCSK9 inhibitors or inclisiran
- Patients diagnosed with moderate or severe calcific aortic stenosis based on non-enhanced Cardiac CT scan
- Willing and able to understand the Participant Information Sheet and provide informed consent
- Agree to comply with blood sample collection for assessments
- Do not meet any exclusion criteria
You will not qualify if you...
- Unable to provide valid informed consent
- Patients under 18 years of age
- Significant neurological, hepatic, renal, endocrine, gastrointestinal, pulmonary, hemorrhagic, metabolic or other disease likely to affect study results
- History or signs of substance abuse or psychiatric disease
- Alcohol consumption above 14 units per week
- Any significant illness during the 4 weeks before screening
- Major bleeding disorders or blood abnormalities (platelets < 70 x 109/l, Hb < 8 g/dl, INR > 1.4, APTT > 2 times upper normal limit, leucocyte count < 3.5 x 109/l, neutrophil count < 1 x 109/l)
- Currently enrolled in another investigational device or non-licensed drug trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
East and North Herts NHS Trust
Stevenage, United Kingdom
Actively Recruiting
Research Team
J
Joshua H Leader, MBChB, BSc
CONTACT
D
Diana A Gorog, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here